The risk of turning healthy people into patients

Over treatment of people with low risk indicators increase the risk of their becoming seriously ill.

by John Frank

Expert Advisor

EvidenceNetwork.ca

EDINBURGH, Scotland/ Troy Media/ – Modern medical practice is engaged in a battle, not for hearts and minds, but for the conversion of perfectly healthy people into patients.

However, a substantial majority of these people, labelled “at high risk” of various diseases in the name of prevention, will not benefit despite the significant costs of preventive interventions. In fact, some may be harmed.

This “medicalization” of healthy persons, especially after mid-life, arises largely from ever lower cut-offs for treatment of risk factors for cardiovascular diseases (CVD) – heart attacks and strokes. Modest elevations of blood pressure and blood cholesterol, for example, typically cause no symptoms until they have been present for decades. Over-treatment of these risk factors can do more harm than good.

For example, controversy on both sides of the Atlantic surrounds new thresholds for cholesterol treatment, which recommend the statin family of drugs be taken indefinitely and daily for one quarter to one-third of the healthy older-adult population.

Of specific concern is that millions of additional persons with no symptoms will now be prescribed statins, even though, for many, their absolute risk of cardiovascular disease is quite low, and their first heart attack or stroke is many years to decades away.

The new guidelines are not simple to communicate to patients. But here’s the bottom line: in the UK, there is now a significantly lowered risk-threshold for starting statins -from 20 per cent to 10 per cent – the likelihood that a given healthy patient will have a heart attack or stroke in the next 10 years – and in the U.S. that cut-off is even lower at 7.5 per cent.

Statins do have impressive benefits compared to risks for people who have significantly higher CVD risk levels, and in persons who have had symptoms of heart attack or stroke. But this is not the case for everyone.

What is driving these guideline changes?

The continuing fall in the price of powerful generic statins has converted statins prescribed for these lower risk thresholds into a competitive health economic investment. In other words, the new guidelines meet NICE (National Institute of Health and Care Excellence) criteria in the UK for “quality-adjusted years of life gained, per pound sterling spent.”

The societal cost implications of the new guidelines are, however, breath-taking: £285 million cost annually to the NHS; much more in the U.S.

Guideline advocates claim the guidelines will reduce the rate of heart attacks and strokes in those treated by a third or more. Critics, however, point out that many patients, citing side-effects such as muscle discomfort simply won’t continue taking statins long-term. Also, next to nothing is known about the long-term safety of the newer, high-potency statins. Large groups of patients on statins have only been followed-up for 10 to 15 years, and many of them were on older, less potent statins.

More worrisome, even this limited follow-up has recently found one new case of Type 2 diabetes per 700 person-years of statin treatment. But if it has taken epidemiologists more than two decades to discover the statin/Type 2 diabetes link, what other subtle and delayed side-effects of statin use are we not yet aware of?

Discovery of just one additional side-effect of similar seriousness and frequency would virtually wipe out the net benefits at the new thresholds for statins.

Some physicians and researchers are asking: “Is this really how we want to spend our scarce healthcare resources?” In terms of preventing cardiovascular disease specifically, why not work harder on promoting non-smoking, healthy diet and physical activity instead? These lifestyle risk-factors are reversible without drugs, and still constitute the fundamental “upstream” causes of heart disease. Lifestyle changes population-wide would also yield spin-off benefits in preventing certain cancers and other chronic diseases not affected by statins.

This is where the controversy currently sits. Many physicians are reluctant to follow the new guidance. In the interim, the increased complexity of such closely balanced risks and benefits will require clinicians to more skilfully engage patients’ personal values and preferences before starting statins.

John Frank is an expert advisor with EvidenceNetwork.ca and Chair, Public Health Research and Policy, Medicine and Veterinary Medicine at the University of Edinburgh. His book, Prevention: A (Very) Critical View, will be published by Oxford University Press in late 2015. www.troymedia.com

 

Just Posted

Proposed Boston Flats Eco-Depot hits rezoning amendment hurdle

TNRD now considering way forward after third reading of bylaw defeated

Conservative candidate Brad Vis speaks at Ashcroft Tiwn Hall

Puts family first, says Conservatives will work for all Canadians

New report on 2017 wildfires calls for better coordination with First Nations

Tsilhqot’in National Government documents 2017 disaster and lists 33 calls to action

In 1968, an Ashcroft Art Show was an idea whose time had come

Local artists got together to form a club in 1967, and a year later a show was born

Soccer week 2: League play gets underway

Warm-up time is over as the teams get down to work

VIDEO: Driver in bizarre hit-and-run at B.C. car dealership turns herself in

Police believe alcohol was a factor in incident causing estimated $15,000 in damages

Two in critical condition, several still in hospital after Langley deck collapse

Close relative Satwant Garcha makes daily trips to visit those injured at the wedding

Allegedly intoxicated man arrested after 3 paramedics attacked at Kamloops hospital

Paramedics had transported the man to Royal Inlands Hospital for medical treatment

Canadian privacy watchdogs find major shortcomings in Facebook probe

The probe followed reports that Facebook had let an outside organization use an app to access users’ personal info

B.C., Ottawa talk 50/50 split on abandoned bus-route service

B.C. has paid $2 million on a bus service for the northern part of the province

‘B.C. cannot wait for action’: Top doctor urges province to decriminalize illicit drugs

Dr. Bonnie Henry says current approach in ‘war on drugs’ has criminalized and stigmatized drug users

B.C. woman, 76, challenges alcohol-screening laws after failing to give breath sample

Norma McLeod was unable to provide a sample because of her medical conditions

B.C. youth coach banned amid sexual harassment, bullying scandal: Water Polo Canada

Justin Mitchell can’t take part in Water Polo Canada events or clubs

Wilson-Raybould: Feds want to just ‘manage the problem’ of Indigenous Peoples

Former federal justice minister speaks at First Nations Justice Council meeting in B.C.

Most Read